1.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
		                        		
		                        			 Purpose:
		                        			This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).  
		                        		
		                        			Materials and Methods:
		                        			Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.  
		                        		
		                        			Results:
		                        			This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.  
		                        		
		                        			Conclusion
		                        			This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology. 
		                        		
		                        		
		                        		
		                        	
2.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
		                        		
		                        			 Purpose:
		                        			This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).  
		                        		
		                        			Materials and Methods:
		                        			Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.  
		                        		
		                        			Results:
		                        			This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.  
		                        		
		                        			Conclusion
		                        			This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology. 
		                        		
		                        		
		                        		
		                        	
3.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
		                        		
		                        			 Purpose:
		                        			This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).  
		                        		
		                        			Materials and Methods:
		                        			Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.  
		                        		
		                        			Results:
		                        			This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.  
		                        		
		                        			Conclusion
		                        			This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology. 
		                        		
		                        		
		                        		
		                        	
4.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
		                        		
		                        			 Purpose:
		                        			This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).  
		                        		
		                        			Materials and Methods:
		                        			Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.  
		                        		
		                        			Results:
		                        			This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.  
		                        		
		                        			Conclusion
		                        			This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology. 
		                        		
		                        		
		                        		
		                        	
5.The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center
Min Cheol HAN ; Seo Hee CHOI ; Chae-Seon HONG ; Yong Bae KIM ; Woong Sub KOOM ; Jin Sung KIM ; Jaeho CHO ; Chan Woo WEE ; Changhwan KIM ; Jong Won PARK ; Soorim HAN ; Heejeong LEE ; Hong In YOON ; Ik Jae LEE ; Ki Chang KEUM
Radiation Oncology Journal 2024;42(4):295-307
		                        		
		                        			 Purpose:
		                        			This report offers a detailed examination of the inception and current state of the Heavy-ion Therapy Center (HITC) at the Yonsei Cancer Center (YCC), setting it apart as the world’s first center equipped with a fixed beam and two superconducting gantries for carbon-ion radiation therapy (CIRT).  
		                        		
		                        			Materials and Methods:
		                        			Preparations for CIRT at YCC began in 2013; accordingly, this center has completed a decade of meticulous planning and culminating since the operational commencement of the HITC in April 2023.  
		                        		
		                        			Results:
		                        			This report elaborates on the clinical preparation for adopting CIRT in Korea. It includes an extensive description of HITC’s facility layout at YCC, which comprises the accelerator and treatment rooms. Furthermore, this report delineates the clinical workflow, criteria for CIRT application, and the rigorous quality assurance processes implemented at YCC. It highlights YCC’s sophisticated radiation therapy infrastructure, collaborative initiatives, and the efficacious treatment of >200 prostate cancer cases utilizing CIRT.  
		                        		
		                        			Conclusion
		                        			This manuscript concludes by discussing the prospective influence of CIRT on the medical domain within Korea, spotlighting YCC’s pioneering contribution and forecasting the widespread integration of this groundbreaking technology. 
		                        		
		                        		
		                        		
		                        	
6.Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment
Hyo Seon RYU ; Hyun Jung KIM ; Woong Bae JI ; Byung Chang KIM ; Ji Hun KIM ; Sung Kyung MOON ; Sung Il KANG ; Han Deok KWAK ; Eun Sun KIM ; Chang Hyun KIM ; Tae Hyung KIM ; Gyoung Tae NOH ; Byung-Soo PARK ; Hyeung-Min PARK ; Jeong Mo BAE ; Jung Hoon BAE ; Ni Eun SEO ; Chang Hoon SONG ; Mi Sun AHN ; Jae Seon EO ; Young Chul YOON ; Joon-Kee YOON ; Kyung Ha LEE ; Kyung Hee LEE ; Kil-Yong LEE ; Myung Su LEE ; Sung Hak LEE ; Jong Min LEE ; Ji Eun LEE ; Han Hee LEE ; Myong Hoon IHN ; Je-Ho JANG ; Sun Kyung JEON ; Kum Ju CHAE ; Jin-Ho CHOI ; Dae Hee PYO ; Gi Won HA ; Kyung Su HAN ; Young Ki HONG ; Chang Won HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2024;40(2):89-113
		                        		
		                        			
		                        			 Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee. 
		                        		
		                        		
		                        		
		                        	
7.Radiologic Assessment of Knee Phenotypes Based on the Coronal Plane Alignment of the Knee Classification in a Korean Population
Hong Yeol YANG ; Tae Woong YOON ; Joon Yeong KIM ; Jong Keun SEON
Clinics in Orthopedic Surgery 2024;16(3):422-429
		                        		
		                        			 Background:
		                        			The Coronal Plane Alignment of the Knee (CPAK) classification system has been developed as a comprehensive system that describes 9 coronal plane phenotypes based on constitutional limb alignment and joint line obliquity (JLO). Due to the characteristics of Asian populations, which show more varus and wider distribution in lower limb alignment than other populations, modification of the boundaries of the arithmetic hip-knee-ankle angle (aHKA) and JLO should be considered. The purpose of this study was to determine the knee phenotype in a Korean population based on the original CPAK and modified CPAK classification systems. 
		                        		
		                        			Methods:
		                        			We reviewed prospectively collected data of 500 healthy and 500 osteoarthritic knees between 2021 and 2023 using radiographic analysis and divided them based on the modified CPAK classification system by widening the neutral boundaries of the aHKA to 0° ± 3° and using the actual JLO as a new variable. Using long-leg standing weight-bearing radiographs, 6 radiographic parameters were measured to evaluate the CPAK type: the mechanical HKA angle, medial proximal tibial angle (MPTA), lateral distal femoral angle (LDFA), aHKA, JLO, and actual JLO. 
		                        		
		                        			Results:
		                        			From 2 cohorts of 1,000 knees, the frequency distribution representing all CPAK types was different between the healthy and arthritic groups. The most common categories were type II (38.2%) in the healthy group and type I (53.8%) in the arthritic group based on the original CPAK classification. The left and upward shift in the distribution of knee phenotypes in the original classification was corrected evenly after re-establishing the boundaries of a neutral aHKA and the actual JLO. According to the modified CPAK classification system, the most common categories were type II (35.2%) in the healthy group and type I (38.0%) in the arthritic group. 
		                        		
		                        			Conclusions
		                        			Although the modified CPAK classification corrected the uneven distribution seen when applying the original classification system in a Korean population, the most common category was type I in Korean patients with osteoarthritic knees in both classification systems. Furthermore, there were different frequencies of knee phenotypes among healthy and arthritic knees. 
		                        		
		                        		
		                        		
		                        	
8.The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention
Pil Sang SONG ; Seok-Woo SEONG ; Ji-Yeon KIM ; Soo Yeon AN ; Mi Joo KIM ; Kye Taek AHN ; Seon-Ah JIN ; Jin-Ok JEONG ; Jeong Hoon YANG ; Joo-Yong HAHN ; Hyeon-Cheol GWON ; Woo Jin JANG ; Hyuck Jun YOON ; Jang-Whan BAE ; Woong Gil CHOI ; Young Bin SONG
Korean Circulation Journal 2024;54(4):189-200
		                        		
		                        			 Background and Objectives:
		                        			Concerns remain that early aspirin cessation may be associated with potential harm in subsets at high risk of ischemic events. This study aimed to assess the effects of P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) vs.prolonged DAPT (12-month or longer) based on the ischemic risk stratification, the CHADSP2A2RC, after percutaneous coronary intervention (PCI). 
		                        		
		                        			Methods:
		                        			This was a sub-study of the SMART-CHOICE trial. The effect of the randomized antiplatelet strategies was assessed across 3 CHADS-P2A2RC risk score categories. The primary outcome was a major adverse cardiac and cerebral event (MACCE), a composite of all-cause death, myocardial infarction, or stroke. 
		                        		
		                        			Results:
		                        			Up to 3 years, the high CHADS-P2A2RC risk score group had the highest incidence of MACCE (105 [12.1%], adjusted hazard ratio [HR], 2.927; 95% confidence interval [CI], 1.358–6.309; p=0.006) followed by moderate-risk (40 [1.4%], adjusted HR, 1.786; 95% CI, 0.868–3.674; p=0.115) and low-risk (9 [0.5%], reference). In secondary analyses, P2Y12 inhibitor monotherapy reduced the Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding without increasing the risk of MACCE as compared with prolonged DAPT across the 3 CHADS-P2A2RC risk strata without significant interaction term (interaction p for MACCE=0.705 and interaction p for BARC types 2, 3, or 5 bleeding=0.055). 
		                        		
		                        			Conclusions
		                        			The CHADS-P2A2RC risk score is valuable in discriminating high-ischemicrisk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT. 
		                        		
		                        		
		                        		
		                        	
9.Impact of Atrial Fibrillation on Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): The K-TAVI Registry
Sang Yoon LEE ; Ki Hong CHOI ; Taek Kyu PARK ; Jihoon KIM ; Eun Kyoung KIM ; Sung-Ji PARK ; Seung Woo PARK ; Hyeon-Cheol GWON ; Kiyuk CHANG ; Cheol Woong YU ; JuHan KIM ; Young Jin CHOI ; In-Ho CHAE ; Jae-Hwan LEE ; Jun-Hong KIM ; Jong Seon PARK ; Won-Jang KIM ; Young Won YOON ; Tae Hoon AHN ; Sang Rok LEE ; Byoung Joo CHOI ; Tae-Hyun YANG ; Cheol Ung CHOI ; Seung-Ho HUR ; Seong-Jin OH ; Han Cheol LEE ; HunSik PARK ; Hyo-Soo KIM ; Seung-Hyuk CHOI
Yonsei Medical Journal 2023;64(7):413-422
		                        		
		                        			 Purpose:
		                        			The incidence and prognostic implications of atrial fibrillation (AF) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) are controversial, especially for Korean patients. Furthermore, the pattern of antithrombotic therapy for these patients is unknown. The present study sought to identify the impact of AF on Korean patients undergoing TAVI and demonstrate the status of antithrombotic therapy for these patients. 
		                        		
		                        			Materials and Methods:
		                        			A total of 660 patients who underwent TAVI for severe AS were recruited from the nationwide K-TAVI registry in Korea. The enrolled patients were stratified into sinus rhythm (SR) and AF groups. The primary endpoint was all-cause death at 1-year. 
		                        		
		                        			Results:
		                        			AF was recorded in 135 patients [pre-existing AF 108 (16.4%) and new-onset AF 27 (4.1%)]. The rate of all-cause death at 1 year was significantly higher in patients with AF than in those with SR [16.2% vs. 6.4%, adjusted hazard ratio (HR): 2.207, 95% confidence interval (CI): 1.182–4.120, p=0.013], regardless of the onset timing of AF. The rate of new pacemaker insertion at 1 year was also significantly higher in patients with AF than in those with SR (14.0% vs. 5.5%, adjusted HR: 3.137, 95%CI: 1.621–6.071, p=0.001).Among AF patients, substantial number of patients received the combination of multiple antithrombotic agents (77.8%), and the most common combination was that of aspirin and clopidogrel (38.1%). 
		                        		
		                        			Conclusion
		                        			AF was an independent predictor of 1-year mortality and new pacemaker insertion in Korean patients undergoing TAVI. 
		                        		
		                        		
		                        		
		                        	
10.The pre-hospital analysis of intentional taking poison in Gangwon-do
Woong Chan AHN ; Jun Hwi CHO ; Joong Bum MOON ; Chan Woo PARK ; Myoung Cheol SHIN ; Ka Eul KIM ; Joon Yeol LEE ; Yoon Soo PARK ; Byoung Seon HWANG ; Go Eum YANG ; Hui Young LEE ; Min Soo KIM ; In Kook CHUN ; Taek Geun OHK
Journal of the Korean Society of Emergency Medicine 2020;31(1):23-38
		                        		
		                        			 Objective:
		                        			This study examined the characteristics of the patients taking poison intentionally at the pre-hospital stage to prevent it at the community level. 
		                        		
		                        			Methods:
		                        			We retrospectively reviewed the data that had been reported to fire stations from January 2017 to December 2018. This data included sex, age, occupation, the season of the year, time, place, methods, alcohol ingestion, transferred to the hospital or not, and we examined how taking poison had an effect on the suicide success rate. 
		                        		
		                        			Results:
		                        			The subjects were a total of 1,356 patients who had been reported to fire stations due to intentionally taking poison. Forty-five point five percent of them were male, and 54.5% were female. The most common method of intentional taking poison was sedatives (58.3%), followed by pesticides (24.6%), antidepressants (19.0%), and other methods (12.6%). The home place was preferred more than any other places. The suicide success rate was 2.1% in males and 1.4% in females. For the age groups, those patients 40-64 years old tried taking poison much more than the other age groups. In the aspect of the season of the year, summer was the highest season for taking poison, at 30.3%. The daytime was more preferred than the night time. 
		                        		
		                        			Conclusion
		                        			In this study, we analyzed the characteristics of the pre-hospital intentional poisoning cases according to gender, age, occupation, season of the year, time, and between the transferred and the untransferred groups. Efforts should be made in cooperation with the community to prevent suicide attempts by intentionally taking poison. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail